Sickle Cell Disease

vline gray 1

Since the early 1900s, there has only been one FDA-approved therapy for the prevention of SCD-related complications. Fortunately, this is an historic moment in sickle cell discovery, with the largest pipeline of promising SCD-specific drugs in preclinical and clinical trials in the history of the disease. In addition to targeting hemoglobin polymerization, many of these drugs target the unique erythrocyte adhesive properties that contribute to microvascular obstruction.  Despite this, there is no clinical standard for assessing erythrocyte adhesion. SCD providers will soon have drugs available to prevent and relieve adhesion-mediated complications, therefore there is an urgent need diagnostic tools to guide drug selection for individual patients and monitor therapeutic response.

By using BioFlux, flow adhesion assays for SCD are made easy. The system can be utilized to understand the adhesive properties of sickle erythrocytes in a simulated blood flow environment, and the process is currently being worked on to be standardize for clinical testing. In fact, a US company (Functional Fluidics) has deployed a standardized microfluidic flow-based test into the preclinical and clinical research market. The advances in microfluidic flow-based blood function testing with BioFlux play a crucial role in preclinical drug validation, the potential for applications in sickle cell clinical trials, and ultimately clinical therapy.

Functionalized BioFlux flow channels were used to analyze eryptotic erythrocytes adhering to VWF fibers (Nicolay et al., 2018).

Key BioFlux Advantages For SCD Studies

vline gray 1

Microfluidic Flow-Based Diagnostics Used to Personalize SCD Therapy

1805483116 ee328e2bc184af65632d09749852bbfe3b2e6af647b1608acfd8cff088143ae3 d 840
Webinar discussing advances in microfluidic flow-based blood function testing, the role these tests are play in preclinical drug validation, and the potential for applications in sickle cell clinical trials and ultimately clinical therapy.